YH-25724: 一种FGF21R激动剂、GLP-1R激动剂药物,由Yuhan Corp. (Yuhan Corp.)公司最早进行研发,目前全球最高研发状态为临床1期,作用机制: FGF21R激动剂,GLP-1R激动剂(胰高血糖素样肽-1激动剂),治疗领域: 消化系统疾病,内分泌与代谢疾病,其他疾病,在研适应症: 非酒精性
Given these findings, YH25724, a novel long-acting, well-balanced GLP-1/FGF21 dual agonist, has a complementary and synergistic mechanism of insulin secretion and insulin sensitivity, which is well translated into a potent and sustained glycemic control with the additional benefits of body weight ...
YH25724, a novel long-acting GLP-1/FGF21 dual agonist lowers both non-alcoholic fatty liver disease activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis 来自 学术范 喜欢 0 阅读量: 171 ...
YH25724, a novel long-acting GLP-1/FGF21 dual agonist provides potent and sustained glycaemic control, body weight loss and lipid profile improvement in animal models H.N. Hong, J.H. Kim, H.H. Choi, D. Kim, S. Lim, M. Seo, M.K. Ju, J.Y. Park, B.H. Choi, J.G. Kim, ...
YH25724, a novel long-acting GLP-1/FGF21 dual agonist provides potent and sustained glycaemic control, body weight loss and lipid profile improvement in an... HN Hong,JH Kim,HH Choi,... - Diabetologia: Clinical and Experimental Diabetes and Metabolism = Organ of the European Association for...